Defining the role of the caregiver in Alzheimer's disease treatment
Defining the role of the caregiver in Alzheimer's disease treatment
复制标题
DOI：
10.2165/00002512-200219120-00001
复制
发表时间：
2002-01-01
期刊：
影响因子：
2.8
通讯作者：
Green, A
中科院分区：
文献类型：
--
作者：
Brodaty, H;Green, A
照顾痴呆症患者的日常责任往往会给护理者带来代价，这可能表现在心理、身体、社会和经济上。过去十年见证了治疗阿尔茨海默病的药物的出现，特别是胆碱酯酶抑制剂。护理人员对治疗的开始、实施和监测是不可或缺的。特别是，当病人不再有能力这样做时，他们提供替代的知情同意。虽然有证据表明胆碱酯酶抑制剂可以减轻护理人员的负担和帮助病人的时间，但也有与负责给药的人有关的负担。护理人员是研究阿尔茨海默病药物使用的关键。他们在招募和同意以及监测反应和不利影响方面发挥作用。越来越多地，护理人员本身被认为是评估阿尔茨海默病新药理学药物疗效的合法目标（因为他们的益处已被证明）。护理人员对阿尔茨海默病患者的药物治疗负有责任，并需要有关药物的信息，以便他们能够有现实的期望。医生在为阿尔茨海默病开药时，需要与护理人员和患者合作。
The day-to-day responsibility of caring for a person with dementia often exacts a toll upon the caregiver, which may be manifested psychologically, physically, socially and financially.The last decade has witnessed the advent of drug availability for the treatment of Alzheimer's disease, specifically the cholinesterase inhibitors. Caregivers are integral to the initiation, administration and monitoring of treatment. In particular, they provide substitute informed consent when patients are no longer competent to do so. While there is evidence that cholinesterase inhibitors may reduce caregiver burden and time spent assisting patients, there are also burdens associated with being the person responsible for administering medication.Caregivers are key to research into the use of medications for Alzheimer's disease. They have roles in recruitment and consent and monitoring response and adverse effects. Increasingly, caregivers themselves are recognised as legitimate targets for evaluating the efficacy of new pharmacological agents for Alzheimer's disease (as benefits have been demonstrated for them).Caregivers have responsibilities regarding the drug treatment of patients with Alzheimer's disease, and require information about the medications so that they can have realistic expectations. Doctors need to work in partnership with caregivers and patients when prescribing drugs for Alzheimer's disease.